No Compromises, That’s Our Promise

Dedicated to delivering high quality long, pure DNA to accelerate innovation.

Molecular Assemblies is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. Our patented enzymatic method makes DNA the way nature intended, resulting in long, pure, high-fidelity sequences in less time with no chemical waste.

We’re uncompromising in our mission to enhance reading and writing of long synthetic DNA, so that you can be unconstrained in your mission to innovate and solve complex problems in synthetic biology, precision medicine, agriculture, and emerging applications — like DNA data storage, nanomachines, and bio-based electronics.

Meet the Team

Leadership

Board of Directors

Leadership

Board of Directors

Meet the Team- if no science board

Leadership

Board of Directors

Leadership

Board of Directors

Investors

Featured News

Press release

Molecular Assemblies Ships First Enzymatically Synthesized Oligonucleotides

March 14, 2023

More news >>

Featured Events

CRISPR TECHNOLOGIES CONFERENCE

Cowen’s 43rd Annual Health Care Conference

Boston, MA | March 6-8, 2023

More events >>

Open Positions

We’re hiring

No posts found!

Join our team >>

Floyd E. Romesberg, Ph.D.

Professor of Chemistry, The Scripps Research Institute

Floyd E. Romesberg, Ph.D., is currently a Sanofi scholar at Synthorx, a Sanofi company, where his group works to use the expanded genetic alphabet/code to create novel therapeutics. Romesberg co-founded three biotech companies, Achaogen, RQx Pharmaceutics, and Synthorx.

He has also served as member of Institute for Defense Analysis Defense Science Study Group and has been elected into the National Academy of Inventors. Previously, Romesberg led a research laboratory at Scripps Research that applied organic chemistry, synthetic biology, and biophysics to study different aspects of evolution. Central projects included the evolution of DNA polymerases with novel activities and their use to discover aptamers comprised of modified nucleotides. Of particular significance is his work to expand the genetic alphabet and code through the development of a third DNA base pair that relies on hydrophobic and packing forces as opposed to hydrogen bonding for selective pairing. Romesberg’s research group worked to design, characterize, and optimize unnatural base pair candidates for just over a decade to create a fully functional in vitro six-letter genetic alphabet in 2012. Two years after this success, the Romesberg group reported the first semi-synthetic organism that stably harbors and propagates increased information in its DNA, and in 2017, they further demonstrated that the semi-synthetic organism could retrieve the increased information to synthesize proteins containing non-canonical amino acids.

At Scripps, Romesberg has authored nearly 150 peer-reviewed primary research articles, an additional 33 review articles, and over a dozen patents. He has presented his work at over 220 seminars worldwide, including numerous universities, biotech companies, professional society meetings, and cultural symposia. Romesberg is the recipient the Camille Dreyfus Teacher Scholar Award, the NSF CAREER Award, the ACS Nobel Laureate Signature Award, the ACS San Diego Section Distinguished Scientist Award, and the Royal Society of Chemistry’s Bioorganic Chemistry Award, as well as funding awards from the National Institutes of Health, National Science Foundation, Office of Naval Research, and Defense Advanced Research Projects Agency.

Romesberg received a B.S. and M.S in chemistry from The Ohio State University where he studied organic chemistry with Matthew Platz. He completed his dissertation studies in physical organic chemistry under the direction of David Collum and received a Ph.D. from Cornell University in 1994. Following an NIH postdoctoral position at UC Berkeley, he was appointed a tenure-track position in the Chemistry Department at Scripps Research in La Jolla, California in 1998, where he remained until 2019.

Joe Smith

Advisor

Joe Smith has more than 40 years of business and legal experience. Most recently he was Senior Vice President, Business Development and General Counsel of Cepheid, a leading developer of integrated systems for genetic assessment.

He was previously Executive Vice President, Business Development at Applied Biosystems group of Applera Corporation. In that capacity, he directed the activities of Applied Biosystems in scouting and closing new business opportunities and investments, potential acquisitions, mergers, and collaborations. Prior to his post as the head of business development at Applied Biosystems Group, Mr. Smith held various roles including Assistant Secretary of Applera Corporation and Senior Vice President of Intellectual Property for Applied Biosystems Group (ABI) and its predecessor, PE Biosystems Division of Perkin-Elmer, and Vice President of Intellectual Property for Applied Biosystems, the predecessor of PE Biosystems. During that time, Mr. Smith and his team built the patent portfolio from a handful to more than 400 patents and applications. He was also responsible for designing an out-licensing strategy for the company and implementing a highly successful worldwide patent licensing program for PCR thermal cyclers, PCR reagents, and DNA sequencing.

Prior to his activities with Applied Biosystems, Mr. Smith was a partner at the intellectual property law firm of Wiseman, Jones, and Smith, and the law firm of Boone, Fox, and Jones, and was a member of the technical legal department of Hewlett-Packard. Prior to joining Hewlett-Packard, Mr. Smith was involved in life science research and administration and was a business and scientific consultant to the National Cancer Institute, the American College of Radiology, the Bureau of Radiological Health, the Occupational Safety and Health Administration, and many universities, including for example Stanford University, UCLA, USC, University of Pennsylvania, Northwestern University, University of Minnesota, George Washington University, Emory University, University of Florida, University of North Carolina, University of Texas, and many others.

Mr. Smith holds a B.S. in engineering physics from the University of Arizona; an M.S. in physics and a C. Phil. in theoretical physics from UC San Diego, and a J.D. from Santa Clara University.

No Compromises, That’s Our Promise

Dedicated to delivering high quality long, pure DNA to accelerate innovation.

Meet the Team

Michael J. Kamdar

J. William Efcavitch, Ph.D.

Stephen R. Bates

Leigh F. Elkolli, CPA

Mark Nibbe

Phil Paik, Ph.D.

Larry Stambaugh

Michael J. Kamdar

J. William Efcavitch, Ph.D.

Helge Bastian, Ph.D.

John Nichols

Todd C. Peterson, Ph.D.

Jeffrey Sampson, Ph.D.

Meet the Team- if no science board

Michael J. Kamdar

J. William Efcavitch, Ph.D.

Stephen R. Bates

Leigh F. Elkolli, CPA

Mark Nibbe

Phil Paik, Ph.D.

Larry Stambaugh

Michael J. Kamdar

J. William Efcavitch, Ph.D.

Helge Bastian, Ph.D.

John Nichols

Todd C. Peterson, Ph.D.

Jeffrey Sampson, Ph.D.

Investors

Featured News

Molecular Assemblies Ships First Enzymatically Synthesized Oligonucleotides

Featured Events

Cowen’s 43rd Annual Health Care Conference

Open Positions